Related Experiment Video

Updated: Aug 8, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer

Niels Reinmuth1, Michael Meister, Thomas Muley

  • 1Clinic for Thoracic Diseases, University of Heidelberg, Heidelberg, Germany. niels.reinmuth@thoraxklinik-heidelberg.de

International Journal of Cancer
|March 25, 2006
PubMed

Insights

Identifying molecular alterations in non-small cell lung cancer (NSCLC) is key. These biomarkers can help predict which patients will respond to receptor tyrosine kinase inhibitors (RTKIs), enabling personalized treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Receptor tyrosine kinases (RTKs) are crucial in cell signaling and frequently deregulated in non-small cell lung cancer (NSCLC).
  • RTKs are expressed not only by cancer cells but also by stromal cells, which can influence tumor behavior.
  • While RTK inhibitors (RTKIs) show promise, only a subset of NSCLC patients benefit, necessitating predictive markers.

Purpose of the Study:

  • To review current data on molecular alterations as predictive biomarkers for RTKI response in NSCLC.
  • To highlight the importance of identifying specific patient populations likely to respond to targeted therapies.

Main Methods:

  • Review of existing clinical and preclinical data on RTK alterations in NSCLC.
  • Analysis of molecular changes in both cancer and stromal cells relevant to RTKI efficacy.
  • Exploration of genetic mutations, gene amplification, receptor expression, and signaling pathway modifications.

Main Results:

  • Molecular alterations in cancer cells, such as specific mutations or amplifications, are being investigated as key response markers.
  • The role of stromal cell-expressed RTKs and their impact on treatment outcomes requires further investigation.
  • Current research focuses on identifying a panel of molecular markers for patient stratification.

Conclusions:

  • Defined molecular alterations hold significant potential as surrogate markers for predicting RTKI response in NSCLC.
  • These markers are essential for developing individualized therapeutic approaches and improving treatment efficacy in NSCLC patients.
  • Future research should focus on validating these markers for clinical application in personalized oncology.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...